de Morais SM - Search Results

1

Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.

de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. de Morais SM, et al. Clin Pharmacol Ther. 1995 Oct;58(4):404-11. doi: 10.1016/0009-9236(95)90053-5. Clin Pharmacol Ther. 1995. PMID: 7586932

2

Biochemistry and molecular biology of the human CYP2C subfamily.

Goldstein JA, de Morais SM. Goldstein JA, et al. Among authors: de morais sm. Pharmacogenetics. 1994 Dec;4(6):285-99. doi: 10.1097/00008571-199412000-00001. Pharmacogenetics. 1994. PMID: 7704034 Review.

3

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. De Morais SM, et al. Mol Pharmacol. 1994 Oct;46(4):594-8. Mol Pharmacol. 1994. PMID: 7969038

4

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. de Morais SM, et al. J Biol Chem. 1994 Jun 3;269(22):15419-22. J Biol Chem. 1994. PMID: 8195181 Free article.

5

Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.

Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Goldstein JA, et al. Among authors: de morais sm. Pharmacogenetics. 1997 Feb;7(1):59-64. doi: 10.1097/00008571-199702000-00008. Pharmacogenetics. 1997. PMID: 9110363

6

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA. Ferguson RJ, et al. Among authors: de morais sm. J Pharmacol Exp Ther. 1998 Jan;284(1):356-61. J Pharmacol Exp Ther. 1998. PMID: 9435198

7

Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.

de Morais SM, Schweikl H, Blaisdell J, Goldstein JA. de Morais SM, et al. Biochem Biophys Res Commun. 1993 Jul 15;194(1):194-201. doi: 10.1006/bbrc.1993.1803. Biochem Biophys Res Commun. 1993. PMID: 8333835

8

A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.

Brøsen K, de Morais SM, Meyer UA, Goldstein JA. Brøsen K, et al. Among authors: de morais sm. Pharmacogenetics. 1995 Oct;5(5):312-7. doi: 10.1097/00008571-199510000-00007. Pharmacogenetics. 1995. PMID: 8563772

9

Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans.

Edeki TI, Goldstein JA, de Morais SM, Hajiloo L, Butler M, Chapdelaine P, Wilkinson GR. Edeki TI, et al. Among authors: de morais sm. Pharmacogenetics. 1996 Aug;6(4):357-60. doi: 10.1097/00008571-199608000-00009. Pharmacogenetics. 1996. PMID: 8873222 No abstract available.

10

Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.

Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA. Kaminsky LS, et al. Among authors: de morais sm. Mol Pharmacol. 1993 Feb;43(2):234-9. Mol Pharmacol. 1993. PMID: 8429826

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters